Pre-clinical Studies

HitGen's In Vivo team consists of experienced scientists and researchers focused on in vivo pharmacokinetics, efficacy and toxicity evaluation. The team has advanced experimental platforms, such as SPF experimental animal barrier system (ABSL-2 laboratory) and related instruments and equipment, and is proficient in the relevant technical means of animal experiments. Relying on the platform, HitGen has established animal models for various disease types, including tumor models, autoimmune and inflammation models, kidney disease models, metabolic disease models, etc. With deep technology accumulation and innovation ability, HitGen has demonstrated excellent scientific research strength and efficient transformation ability in drug discovery and development, has supported a number of self-developed new drug projects receiving IND approval and entering clinical trial stage, and help customers to carry out small molecules, PROTAC, small nucleic acid and other types of new drug development.

l  Experimental platform

Ø  SPF experimental animal barrier system (ABSL-2 laboratory)

Ø  Instruments and equipment (Small animal anesthesia machine, In Vivo Imaging System, Automatic biochemical analyzer, Multi-channel physiological signal acquisition and processing system)

l  Technical means

Ø  Common routes of administration (oral, intraperitoneal injection, subcutaneous injection, intravenous injection, intratumoral injection)

Ø  Specific route of administration (Intracerebroventricular, Intrathecal injection, Intratracheal injection)

Ø  PD marker detection (WB, qPCR, FC, ELISA, IHC, etc.)

l  In vivo pharmacokinetics

Ø  Common PK in mouse and rat

Ø  Cassette PK

Ø  Tissue distribution/PK

Ø  Excretion (urine, feces)

l  In vivo pharmacodynamics

Ø  Tumor models

ž   Syngeneic models

ž   Cell line-derived xenograft (CDX)

ž   Orthotopic model

Ø  Autoimmune and inflammation models

ž   Imiquimod (IMQ)-induced psoriasis

ž   IL-23-induced psoriasis

ž   Collagen-induced arthritis (CIA)

ž   Antigen-induced arthritis (AIA)

ž   Experimental autoimmune encephalomyelitis (EAE)

Ø  Kidney disease models

ž   5/6 Nephrectomy

ž   Unilateral ureteral obstruction (UUO)-induced renal fibrosis

Ø  Fibrosis model (Bleomycin induced-pulmonary fibrosis)

Ø  Metabolic disease models

ž   High cholesterol diet-induced hyperlipemia

ž   db/db mice diabetes

ž   Urate oxidase (Uox) knockout hyperuricemia

ž   Potassium oxonate and adenine-induced hyperuricemia

Ø  Hypertension model (Angiotensin II infusion model of hypertension)

l  non-GLP toxicity

Ø  Single dose toxicity

Ø  Repeated dose toxicity

Ø  Toxicokinetic

Ø  Genotoxicity (Ames、Mini-Ames)